2020
DOI: 10.3892/or.2020.7668
|View full text |Cite
|
Sign up to set email alerts
|

Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma

Abstract: Ovarian carcinomas have the poorest prognosis and the highest mortality among gynecological malignancies. Neoadjuvant chemotherapy (NACT) is considered as a novel therapeutic strategy and an alternative treatment for advanced epithelial ovarian cancer (AEOC). The aim of the present study was to identify the core genes related to platinum-based NACT resistance in AEOC and to allow screening at the molecular level for the most appropriate ovarian cancer patients for NACT. We obtained three drug-resistant microar… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 78 publications
0
2
0
Order By: Relevance
“…Even though NACT was associated with a significant improvement in complete cytoreduction rates, this was not translated into survival benefit in the general patient population. This could be attributed to two main reasons: 1) the low rates of complete cytoreduction, as discussed above, and 2) the increased chemo-resistance observed in women treated with NACT, especially those with high-grade serous ovarian carcinomas (28)(29)(30). Platinum-resistant or platinum-refractory disease is usually observed in women with high tumour load and serous subtype, as well as in women treated with multiple cycles of chemotherapy.…”
Section: Discussionmentioning
confidence: 99%
“…Even though NACT was associated with a significant improvement in complete cytoreduction rates, this was not translated into survival benefit in the general patient population. This could be attributed to two main reasons: 1) the low rates of complete cytoreduction, as discussed above, and 2) the increased chemo-resistance observed in women treated with NACT, especially those with high-grade serous ovarian carcinomas (28)(29)(30). Platinum-resistant or platinum-refractory disease is usually observed in women with high tumour load and serous subtype, as well as in women treated with multiple cycles of chemotherapy.…”
Section: Discussionmentioning
confidence: 99%
“…This is done by running the loop once and looping through it a k-number of times and getting different performance values for each different test set (Figure 4). Then finally, the average value of all performance values is taken, which reveals how good or bad the model is [28,29]. The formula evaluation score mentioned below:…”
Section: -4-6-cvmentioning
confidence: 99%